Value of montelukast as a potential treatment of post-COVID-19 persistent cough: a non-randomized controlled pilot study

Value of montelukast as a potential treatment of post-COVID-19 persistent cough: a non-randomized controlled pilot study

Abstract Background This pilot study included 68 cases with post-COVID-19 persistent cough (> 8 weeks), randomly allocated into two groups; intervention group (32 patients) received standard cough therapy, and montelukast 10 mg/day for 14 days and control group (36 patients) received only cough s...

Full description

Bibliographic Details
Main Authors: Aliae A. R. Mohamed Hussein, Mohamed Eltaher A. A. Ibrahim, Hoda A. Makhlouf, Nahed A. Makhlouf, Howaida K. Abd-Elaal, Karima M. S. Kholief, Islam G. Sayed
Format: Article
Language:English
Published: SpringerOpen 2022-09-01
Series:The Egyptian Journal of Bronchology
Subjects:
Montelukast
COVID-19
SARS-CoV-2
Post COVID-19
Cough
Cough severity
Online Access:https://doi.org/10.1186/s43168-022-00154-6

Internet

https://doi.org/10.1186/s43168-022-00154-6

Similar Items